PRO

PROJuly 13, 2026

2026 Mid-Year Psychedelic Industry Report

PROApril 6, 2026

2026 Q1 Psychedelic Industry Report

PROJanuary 19, 2026

2025 Year-End Analysis & 2026 Outlook

PROOctober 6, 2025

2025 Q3 Psychedelic Industry Report

PROJanuary 26, 2024

2023: The Psychedelic Industry Report (PRO REPORT)

PROJanuary 26, 2024

The Psychedelic Education Market in 2023 (PRO REPORT)

PROJanuary 26, 2024

Psychedelic Medicine Year End Analysis (PRO REPORT)

PROOctober 23, 2023

Navigating the Psychedelic Landscape: Q3 Psychedelic Industry Report

PROJuly 13, 2023

Breaking Boundaries, Transforming Markets: A Comprehensive Mid-Year Review of the Psychedelic Sector (PRO REPORT)

PROMay 4, 2023

State of the Psychedelic Industry: 2023 Q1 (PRO REPORT)

PROJanuary 18, 2023

The Complete 2022 Stock Market Analysis (PRO REPORT)

PROJanuary 18, 2023

The Public Psychedelic Companies Report (PRO REPORT)

PROJanuary 18, 2023

The Exhaustive Ketamine Clinic Industry Report (PRO REPORT)

PROJanuary 16, 2023

Psychedelic Research in 2022 (PRO REPORT)

PROJanuary 16, 2023

2022: Psychedelic Investment Landscape (PRO REPORT)

PROJanuary 10, 2023

2022: The Year in Psychedelics (PRO REPORT)

PRONovember 18, 2022

REPORT: International Psychedelic Regulations and Politics

BlogJune 16, 2022

PRO: Elon Musk, ARK, Numinus, and More (VIDEO)

BlogJune 9, 2022

PRO: A Closer Look at Awakn Life Sciences + Cybin and Mindmed Updates (VIDEO)

BlogJune 2, 2022

“The Big 3” – A Financial and Pipeline Analysis of $ATAI, $CMPS, and $MNMD

BlogMay 25, 2022

PRO: Mind Medicine Earnings Report Breakdown

BlogMay 20, 2022

PRO: atai Life Sciences Q1 2022 Earnings Report Breakdown

BlogMay 12, 2022

PRO: Rapid Reactions To Compass Pathways’ Earning Report

BlogMay 11, 2022

PRO: A Deeper Dive Into GH Research